• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

减去成年期体重指数——一种预测非肥胖个体非酒精性脂肪性肝病风险的新指标。

Subtracted Adulthood Mass Index - a new index to predict NAFLD risk in non-obese individuals.

作者信息

Kiyak Ata, Elibol Serra, Barutcu Ozlem, Saruc Murat, Tozun Nurdan

机构信息

Acibadem University School of Medicine, Istanbul, Turkey.

Department of Radiology, Acibadem University School of Medicine; Istanbul, Turkey.

出版信息

Hepatol Forum. 2021 Jan 8;2(1):26-30. doi: 10.14744/hf.2020.2020.0031. eCollection 2021 Jan.

DOI:10.14744/hf.2020.2020.0031
PMID:35782892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9138927/
Abstract

BACKGROUND AND AIM

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease. The aims of the current study are to determine the relationship between NAFLD in non-obese individuals and weight gain during adulthood and develop a new index for the identification of NAFLD risk.

MATERIALS AND METHODS

For this cross-sectional study, 362 patients who underwent abdominal ultrasonography (USG) in our clinic were included. Seventy-eight individuals were obese (>30 kg/m). A history of weight gain during adulthood and systemic metabolic diseases was collected at the time of the study. A new index termed "Subtracted Adulthood Mass Index" (SAMI) was created to estimate the risk of NAFLD development for non-obese people. SAMI is the ratio of the difference between the individual's current weight and his/her weight at 20 years old to his/her height squared (kg/m).

RESULTS

When the SAMI cut-off was set at 3 kg/m, the sensitivity for predicting NAFLD risk was 85.2%, the specificity was 66.9%, the PPV was 79.1%, and the NPV was 75.4%.

CONCLUSION

In this innovational study, a new index named SAMI was developed to identify non-obese people who are at risk of developing NAFLD. The SAMI is easy to calculate and appropriate for clinical use.

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)是一种常见的慢性肝病。本研究的目的是确定非肥胖个体中NAFLD与成年期体重增加之间的关系,并开发一种用于识别NAFLD风险的新指标。

材料与方法

在这项横断面研究中,纳入了362例在我院接受腹部超声检查(USG)的患者。78例为肥胖者(>30kg/m)。在研究时收集成年期体重增加史和全身代谢疾病史。创建了一个名为“减去成年体重指数”(SAMI)的新指标,以评估非肥胖人群发生NAFLD的风险。SAMI是个体当前体重与20岁时体重之差与身高平方的比值(kg/m)。

结果

当SAMI临界值设定为3kg/m时,预测NAFLD风险的敏感性为85.2%,特异性为66.9%,阳性预测值为79.1%,阴性预测值为75.4%。

结论

在这项创新性研究中,开发了一种名为SAMI的新指标,以识别有发生NAFLD风险的非肥胖人群。SAMI易于计算,适用于临床应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b0f/9138927/4d92ce2c74ce/hf-2-26-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b0f/9138927/5d1ee1d8c9a1/hf-2-26-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b0f/9138927/4d92ce2c74ce/hf-2-26-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b0f/9138927/5d1ee1d8c9a1/hf-2-26-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b0f/9138927/4d92ce2c74ce/hf-2-26-g002.jpg

相似文献

1
Subtracted Adulthood Mass Index - a new index to predict NAFLD risk in non-obese individuals.减去成年期体重指数——一种预测非肥胖个体非酒精性脂肪性肝病风险的新指标。
Hepatol Forum. 2021 Jan 8;2(1):26-30. doi: 10.14744/hf.2020.2020.0031. eCollection 2021 Jan.
2
Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease.非酒精性脂肪性肝病瘦型中国成年人的患病率、临床特征、危险因素和指标。
World J Gastroenterol. 2020 Apr 21;26(15):1792-1804. doi: 10.3748/wjg.v26.i15.1792.
3
Weigh change across adulthood is related to the presence of NAFLD: results from NHANES III.成年后的体重变化与 NAFLD 的存在有关:来自 NHANES III 的结果。
J Transl Med. 2023 Feb 23;21(1):142. doi: 10.1186/s12967-023-04007-8.
4
Weight Change across Adulthood in Relation to Non-Alcoholic Fatty Liver Disease among Non-Obese Individuals.成年期体重变化与非肥胖个体非酒精性脂肪性肝病的关系。
Nutrients. 2022 May 20;14(10):2140. doi: 10.3390/nu14102140.
5
Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults.韩国成年人中,根据体重指数,非酒精性脂肪性肝病与代谢综合征各组分的关系。
Am J Gastroenterol. 2012 Dec;107(12):1852-8. doi: 10.1038/ajg.2012.314. Epub 2012 Oct 2.
6
[Prevalence of nonalcoholic fatty liver disease and metabolic abnormalities in 387 obese children and adolescents in Beijing, China].[中国北京387名肥胖儿童及青少年的非酒精性脂肪性肝病患病率及代谢异常情况]
Zhonghua Liu Xing Bing Xue Za Zhi. 2013 May;34(5):446-50.
7
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.瘦型非酒精性脂肪性肝病患者的肝脏和心血管损伤,及其与内脏肥胖的关系。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.
8
The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood.体重增加对成年早期和晚期非酒精性脂肪性肝病和代谢综合征的影响。
Diabetes Res Clin Pract. 2016 Jun;116:183-91. doi: 10.1016/j.diabres.2016.04.047. Epub 2016 Apr 30.
9
Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?非酒精性脂肪性肝病患者家庭成员的筛查可发现其中未被诊断的非酒精性脂肪性肝病:是否存在遗传联系?
J Clin Exp Hepatol. 2021 Jul-Aug;11(4):466-474. doi: 10.1016/j.jceh.2020.10.003. Epub 2020 Oct 10.
10
PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS.甘油三酯-葡萄糖指数在肥胖患者非酒精性脂肪性肝病诊断和分期中的作用。
Arq Gastroenterol. 2021 Apr-Jun;58(2):139-144. doi: 10.1590/S0004-2803.202100000-24.

引用本文的文献

1
Efficacy of orlistat for the treatment of metabolic dysfunction-associated steatotic liver disease patients: A systematic review and meta-analysis.奥利司他治疗代谢功能障碍相关脂肪性肝病患者的疗效:一项系统评价和荟萃分析。
Hepatol Forum. 2025 May 22;6(3):129-136. doi: 10.14744/hf.2024.2024.0047. eCollection 2025.

本文引用的文献

1
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.全球非肥胖或消瘦非酒精性脂肪性肝病的患病率、发病率和结局:系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12.
2
Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations.非酒精性脂肪性肝病:日益加重的负担、不良后果及关联
J Clin Transl Hepatol. 2020 Mar 28;8(1):76-86. doi: 10.14218/JCTH.2019.00051. Epub 2019 Dec 28.
3
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
全球视角下的非酒精性脂肪性肝病和非酒精性脂肪性肝炎。
Hepatology. 2019 Jun;69(6):2672-2682. doi: 10.1002/hep.30251.
4
Nonobese Fatty Liver Disease.非肥胖性脂肪肝疾病。
Clin Gastroenterol Hepatol. 2017 Apr;15(4):474-485. doi: 10.1016/j.cgh.2016.08.028. Epub 2016 Aug 28.
5
Non-alcoholic fatty liver disease in 2015.2015年的非酒精性脂肪性肝病
World J Hepatol. 2015 Jun 18;7(11):1450-9. doi: 10.4254/wjh.v7.i11.1450.
6
Association of weight gain since age 20 with non-alcoholic fatty liver disease in normal weight individuals.20岁以后体重增加与正常体重个体非酒精性脂肪性肝病的关联。
J Gastroenterol Hepatol. 2015 May;30(5):909-17. doi: 10.1111/jgh.12861.
7
Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.孟加拉国非肥胖型非酒精性脂肪性肝病患者的临床、人体测量学、生化及组织学特征
Indian J Gastroenterol. 2014 Sep;33(5):452-7. doi: 10.1007/s12664-014-0488-5. Epub 2014 Jul 15.
8
Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects.与非肥胖受试者中非酒精性脂肪性肝病发生和消退相关的临床和代谢因素。
Liver Int. 2014 Apr;34(4):604-11. doi: 10.1111/liv.12454. Epub 2014 Jan 24.
9
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease.非酒精性脂肪性肝病(NAFLD)及其与胰岛素抵抗、血脂异常、动脉粥样硬化和冠心病的关系。
Nutrients. 2013 May 10;5(5):1544-60. doi: 10.3390/nu5051544.
10
Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease.瘦型非酒精性脂肪性肝病(Lean-NAFLD):隐源性肝病的主要病因。
Acta Gastroenterol Belg. 2011 Sep;74(3):389-94.